EA200000628A1 - Ингибиторы металлопротеаз матрикса - Google Patents

Ингибиторы металлопротеаз матрикса

Info

Publication number
EA200000628A1
EA200000628A1 EA200000628A EA200000628A EA200000628A1 EA 200000628 A1 EA200000628 A1 EA 200000628A1 EA 200000628 A EA200000628 A EA 200000628A EA 200000628 A EA200000628 A EA 200000628A EA 200000628 A1 EA200000628 A1 EA 200000628A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
matrix
metalloproteasis
mmp
solvates
Prior art date
Application number
EA200000628A
Other languages
English (en)
Other versions
EA002971B1 (ru
Inventor
Майкл Джонатан Фрей
Роджер Питер Дикинсон
Кевин Нейл Дэк
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800510.1A external-priority patent/GB9800510D0/en
Priority claimed from GBGB9811843.3A external-priority patent/GB9811843D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200000628A1 publication Critical patent/EA200000628A1/ru
Publication of EA002971B1 publication Critical patent/EA002971B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Соединения формулы (I) или их фармацевтически приемлемые соли, или сольваты любых из них, где заместители имеют значения, определенные в описании, полезны в качестве ингибиторов металлопротеаз матрикса (ММР).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000628A 1998-01-09 1998-12-23 Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения EA002971B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9800510.1A GB9800510D0 (en) 1998-01-09 1998-01-09 Therapeutic agents
GBGB9811843.3A GB9811843D0 (en) 1998-06-02 1998-06-02 Therapeutic agents
PCT/EP1998/008565 WO1999035124A1 (en) 1998-01-09 1998-12-23 Matrix metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
EA200000628A1 true EA200000628A1 (ru) 2001-02-26
EA002971B1 EA002971B1 (ru) 2002-12-26

Family

ID=26312925

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000628A EA002971B1 (ru) 1998-01-09 1998-12-23 Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения

Country Status (37)

Country Link
US (1) US6350907B1 (ru)
EP (1) EP1047665B1 (ru)
JP (1) JP3621884B2 (ru)
KR (1) KR100385662B1 (ru)
CN (1) CN1284942A (ru)
AP (1) AP1059A (ru)
AR (1) AR014270A1 (ru)
AT (1) ATE252547T1 (ru)
AU (1) AU736511B2 (ru)
BG (1) BG104575A (ru)
BR (1) BR9813719A (ru)
CA (1) CA2317604C (ru)
CO (1) CO4990971A1 (ru)
CZ (1) CZ20002459A3 (ru)
DE (1) DE69819206T2 (ru)
DK (1) DK1047665T3 (ru)
DZ (1) DZ2701A1 (ru)
EA (1) EA002971B1 (ru)
ES (1) ES2209244T3 (ru)
HN (1) HN1998000199A (ru)
HR (1) HRP20000460A2 (ru)
HU (1) HUP0101300A3 (ru)
IL (1) IL136889A0 (ru)
IS (1) IS5531A (ru)
MA (1) MA26594A1 (ru)
NO (1) NO20003506D0 (ru)
NZ (1) NZ504683A (ru)
OA (1) OA11435A (ru)
PA (1) PA8466101A1 (ru)
PE (1) PE20000176A1 (ru)
PL (1) PL342763A1 (ru)
PT (1) PT1047665E (ru)
SI (1) SI1047665T1 (ru)
SK (1) SK10112000A3 (ru)
TN (1) TNSN99002A1 (ru)
TR (1) TR200001909T2 (ru)
WO (1) WO1999035124A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140984T3 (da) * 1998-12-31 2003-05-26 Aventis Pharma Inc Selektive inhibitorer af MMP-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
HRP20030696A2 (en) * 2001-02-16 2005-04-30 NPS Allelix Corp. Allelix Neuroscience GlyT-1 INHIBITORS
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7786121B2 (en) * 2003-08-23 2010-08-31 Vernalis (Oxford) Limited Derivatives of hydroxamic acid as metalloproteinase inhibitors
JP2010506147A (ja) * 2006-09-29 2010-02-25 エフ．ホフマン−ラ ロシュ アーゲー 関節リウマチを有する患者のための疾患進行のリスク評価
CN104788333B (zh) * 2015-03-19 2017-03-22 中国医科大学 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途
CN116287790B (zh) * 2023-03-22 2025-04-25 云南奥宇环保科技有限公司 一种溶剂萃取锗并制取锗精矿的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
EP0671911A4 (en) 1992-11-25 1996-08-21 Merck & Co Inc CARBOXYPEPTIDYL DERIVATIVES AS AN ANTIDEGENERATIVE ACTIVE SUBSTANCES.
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
AU6575394A (en) 1993-04-27 1994-11-21 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (ru) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Ингибиторы матричных металлопротеаз и фармацевтическая композиция на их основе
PT822186E (pt) 1994-01-20 2000-08-31 British Biotech Pharm L-tert-leucina-2-piridilamida
EP0905126B1 (en) 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5461746A (en) * 1995-01-17 1995-10-31 Tdw Delaware, Inc. Magnetic cleaning pig
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
AU710502B2 (en) 1995-05-10 1999-09-23 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and TNF liberation and their therapeutic use
EP0826000B1 (en) 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors

Also Published As

Publication number Publication date
IL136889A0 (en) 2001-06-14
NO20003506L (no) 2000-07-07
HUP0101300A3 (en) 2002-11-28
AU736511B2 (en) 2001-07-26
JP2002500215A (ja) 2002-01-08
HN1998000199A (es) 2000-11-03
PL342763A1 (en) 2001-07-02
DE69819206T2 (de) 2004-04-15
HUP0101300A2 (hu) 2001-08-28
DZ2701A1 (fr) 2003-09-01
SK10112000A3 (sk) 2002-02-05
TNSN99002A1 (fr) 2005-11-10
ATE252547T1 (de) 2003-11-15
BR9813719A (pt) 2000-10-17
BG104575A (en) 2001-02-28
SI1047665T1 (en) 2004-02-29
EP1047665A1 (en) 2000-11-02
NO20003506D0 (no) 2000-07-07
CA2317604C (en) 2004-12-21
EP1047665B1 (en) 2003-10-22
DE69819206D1 (de) 2003-11-27
MA26594A1 (fr) 2004-12-20
PE20000176A1 (es) 2000-03-10
ES2209244T3 (es) 2004-06-16
WO1999035124A1 (en) 1999-07-15
TR200001909T2 (tr) 2000-12-21
IS5531A (is) 2000-06-13
HRP20000460A2 (en) 2001-06-30
AU2277699A (en) 1999-07-26
KR100385662B1 (ko) 2003-05-28
KR20010033990A (ko) 2001-04-25
CA2317604A1 (en) 1999-07-15
OA11435A (en) 2004-04-28
AR014270A1 (es) 2001-02-07
CZ20002459A3 (cs) 2001-12-12
CN1284942A (zh) 2001-02-21
NZ504683A (en) 2002-06-28
AP9901436A0 (en) 1999-03-31
DK1047665T3 (da) 2004-02-02
EA002971B1 (ru) 2002-12-26
US6350907B1 (en) 2002-02-26
AP1059A (en) 2002-04-22
PA8466101A1 (es) 2000-05-24
JP3621884B2 (ja) 2005-02-16
CO4990971A1 (es) 2000-12-26
PT1047665E (pt) 2004-01-30

Similar Documents

Publication Publication Date Title
DK0931788T3 (da) Metalloproteasehæmmere
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
MX9700557A (es) Dihidrobenzofuranos.
DE60313472D1 (de) Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
EA200300337A1 (ru) Полиарилкарбоксамиды, применимые в качестве агентов, снижающих содержание липидов
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
EA200301100A1 (ru) Новые фталазиноны
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
MY128164A (en) Compounds
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
ATE259813T1 (de) Triazolopyrimidinderivate
DK0490816T3 (da) Fluorforbindelser som aromatase-inhibitorer.
EA200100051A1 (ru) Ингибиторы fkbp
DK1377574T3 (da) 6-phenylbenzonaphtyridiner
ATE320422T1 (de) Metalloproteinase inhibitoren
MXPA05006957A (es) Nuevos derivados de fosforamida.
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
EA200100073A1 (ru) Изохинолины в качестве ингибиторов урокиназы
ATE243698T1 (de) 1,2-dihydro-1-oxo-pyrazino(1,2-)indolederivate
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
ATE238781T1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU